Wave life sciences reports q4 loss per share of $1.65

Wave life sciences reports fourth quarter and full year 2019 financial results and provides business update.qtrly loss per share $1.65.32 mg data from both precision-hd clinical trials on track for 2h 2020.two additional cns programs − snp3 and c9orf72 − on track to initiate clinical development in 2h 2020.wave life sciences- expects that existing cash, cash equivalents, will enable co to fund operating, capex requirements into q3 of 2021.q4 earnings per share view $-1.43 -- refinitiv ibes data.
WVE Ratings Summary
WVE Quant Ranking